Evaluating the clinical trends and benefits of low‐dose computed tomography in lung cancer patients

1610 Background: Low dose computed tomography (LDCT) scans have reduced lung cancer deaths by 20.3% in high risk populations, although there is an unknown balance between the benefits and harms of LDCT scans as a screening tool. Our purpose was to compare health-related QOL issues among lung cancer patients who were initially detected by LDCT scans; 4 comparison groups included: lung cancer diagnosed by a screening chest X-ray, as an incidental finding from procedures taken for other medical reasons, or based on symptoms indicative for lung cancer and routinely diagnosed, and individuals who were LDCT screened but found no lung cancer (controls who participated in Mayo’s lung cancer CT screening trial). Methods: A total of 1,658 lung cancer patients (cared at Mayo Clinic) in the 4 groups (37, 151, 389, and 1081 respectively) and 488 controls were compared on following patient-reported outcomes (collected via validated tools): overall QOL, four symptoms (cough, pain, dyspnea, fatigue), mental/ physical/ emotional/ social/ spiritual QOL, and other concerns (e.g., family/ friends/ financial/ legal). A clinically significant deficit was defined as at least 10-points in difference (or <50 points) on a 0-100 scale. The rates of deficits were compared via Fisher’s exact tests and average QOL values via Kruskal-Wallis tests. Results: Overall QOL and individual symptoms were significantly worse (p<0.05) in all lung cancer groups than in controls, except for pain. LDCT-screened patients reported the greatest deficit among the 4 lung cancer groups in physical (41%), emotional (24%), social (38%), and spiritual QOL (24%); whereas chest X-ray detected patients had the least deficit in overall QOL (22%) and pain (32%). All 4 lung cancer groups experienced much worse fatigue (52-64%) than the controls (32%). Conclusions: Our preliminary results suggest that LDCT-screening detected lung cancer patients reported a different QOL profile from other lung cancer patients and non-lung cancer controls. The clinical course, smoking behavior, and QOL related health issues associated with LDCT screening for lung cancer warrant thorough investigation.

Download Full-text

A kis dózisú komputertomográfiával történő tüdőrákszűrés költségvetési hatása

Orvosi Hetilap ◽

10.1556/650.2021.32095 ◽

2021 ◽

Vol 162 (24) ◽

pp. 952-959

Author(s):

Balázs Nagy ◽

László Szilbehorn ◽

Anna Kerpel-Fronius ◽

Mariann Moizs ◽

Gábor Bajzik ◽

...

Keyword(s):

Computed Tomography ◽

Lung Cancer ◽

Cancer Patients ◽

Impact Analysis ◽

Low Dose ◽

Target Population ◽

Lung Cancer Patients ◽

Patient Pathways ◽

The Cost ◽

Low Dose Computed Tomography

Összefoglaló. Bevezetés: Korábbi vizsgálatunk szerint a kis dózisú komputertomográfiával évente végzett tüdőrákszűrés 50–74 éves dohányzók körében költséghatékony, és az 55–74 évesek körében költségmegtakarító. Célkitűzés: Ennek a vizsgálatnak a célja a korábbi hosszú távú költséghatékonysági elemzés kiegészítése egy finanszírozó szempontú, rövid és középtávú költségvetési hatásvizsgálattal. Módszer: Egészség-gazdaságtani modellünk az 50–74 éves, naponta dohányzó lakosság tüdőrákszűrésének költségét hasonlítja össze a szervezett szűrésben nem részesülő, naponta dohányzó lakosság költségével. Ehhez megvizsgáljuk a célpopuláció létszámának alakulását, az eredményes elérés és felfedezés valószínűségét, továbbá a szűrés nyomán felmerülő terápiás költségeket és megtakarításokat. A szűrés és a kivizsgálások után diagnosztizált betegek útját az érvényben lévő hazai ellátási protokollnak megfelelően követjük. A kezelések eredményességét a HUNCHEST-felmérés adatai alapján, a kezelésekhez tartozó beavatkozások költségét közfinanszírozási adatok alapján számoljuk. Eredmények: A kis dózisú komputertomográfiával történő tüdőrákszűrés az érintett lakosság 10%-ának várható részvétele mellett a kezdeti évben mintegy 3,3 milliárd, az 5. évben 1,9 milliárd Ft éves többletkiadással jár. A 3. évig szűréssel felfedezett betegek terápiája többe kerül, mint a szűrés nélkülieké, ugyanakkor a 4. és 5. évben a szűrés nélküli csoportban a későbbi stádiumban felismert betegek kezelési költsége már meghaladja a szűrt betegek terápiás költségét. A 3. évtől folyamatosan növekvő terápiás megtakarítás a teljes szűrés költségét a 10. évre az 1. év kiadásának 20%-ára csökkenti. Következtetések: A kis dózisú komputertomográfiával történő tüdőrákszűrés bevezetése évi 2,6 milliárd Ft többletforrást igényelne, és folyamatos kiadáscsökkenés mellett hosszú távon akár nettó megtakarítást is eredményezhet a nem szervezett szűréshez képest. A kockázati csoportok pontosítása, például kiemelt földrajzi területeken végzett célzott szűrés tovább javíthatja az eredményeket. Orv Hetil. 2021; 162(24): 952–959. Summary. Introduction: Our earlier analysis indicated that screening lung cancer patients with low-dose computed tomography amongst smokers between age of 50–74 and between age of 55–74 is cost-effective and cost-saving, respectively. Objective: This study aims to extend the long-term cost-effectiveness analysis with short- and mid-term budget impact analysis. Method: The health economic model compares the cost of nationwide screening amongst smokers between 50–74 years to the current occasional screening policy. The analysis determines the size of the target population, recruitment rates and market uptake. Health care finance costs associated with the patient pathways are determined by national guidelines and clinical practice. Screening and treatment effectiveness are based on the HUNCHEST survey and international scientific literature, while the cost of health states and events are determined using national tariffs. Results: Assuming 10% uptake of low-dose computed tomography screening for the target population will cost an additional 3.3 billion HUF and 1.9 billion HUF in the 1st and 5th years, respectively. Until the 3rd year, new patients’ treatment costs exceed costs due to late discovery and delay in treatment. This pattern is changing from the 4th year on. Due to timely care savings by the 10th year in the screened population will reduce total costs to the 20% of the first year costs. Conclusions: Introduction of national screening for lung cancer patients with low-dose computed tomography is estimated to cost around additional 2.6 billion HUF/year and could end up in net savings in the long run. Identification of risk groups according to regional or other strata could increase the effectiveness and efficiency of the program. Orv Hetil. 2021; 162(24): 952–959.

Download Full-text

36PD New demographic characteristics of lung cancer patients in East Asia? Practice of low-dose spiral computed tomography screening in Shanghai major hospitals

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(18)30316-2 ◽

2018 ◽

Vol 13 (4) ◽

pp. S20-S21

Author(s):

X. Luo

Keyword(s):

Computed Tomography ◽

Lung Cancer ◽

East Asia ◽

Cancer Patients ◽

Low Dose ◽

Demographic Characteristics ◽

Spiral Computed Tomography ◽

Spiral Computed ◽

Lung Cancer Patients

Download Full-text

Faculty Opinions recommendation of Diagnostic performance of low-dose computed tomography screening for lung cancer over five years.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718447501.793516644 ◽

2016 ◽

Author(s):

David Midthun

Keyword(s):

Computed Tomography ◽

Lung Cancer ◽

Diagnostic Performance ◽

Low Dose ◽

Low Dose Computed Tomography

Download Full-text

Faculty Opinions recommendation of A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725638359.793508418 ◽

2015 ◽

Author(s):

Alexandru Grigorescu

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Low Dose ◽

Phase Ii Trial ◽

Small Cell ◽

Egfr Mutations ◽

Small Cell Lung ◽

Multicentre Phase ◽

Lung Cancer Patients ◽

Oncology Research

Download Full-text

LOW-DOSE COMPUTED TOMOGRAPHY IN MOSCOW FOR LUNG CANCER SCREENING (LDCT-MLCS): BASELINE RESULTS

Problems in oncology ◽

10.37469/0507-3758-2019-65-2-224-233 ◽

2019 ◽

Vol 65 (2) ◽

pp. 224-233

Author(s):

Sergey Morozov ◽

Viktor Gombolevskiy ◽

Anton Vladzimirskiy ◽

Albina Laypan ◽

Pavel Kononets ◽

...

Keyword(s):

Computed Tomography ◽

Lung Cancer ◽

Cancer Screening ◽

Low Dose ◽

Early Stage ◽

Lung Cancer Screening ◽

Stage I ◽

Malignant Neoplasms ◽

Number Needed To Screen ◽

Low Dose Computed Tomography

Study aim. To justify selective lung cancer screening via low-dose computed tomography and evaluate its effectiveness. Materials and methods. In 2017 we have concluded the baseline stage of “Lowdose computed tomography in Moscow for lung cancer screening (LDCT-MLCS)” trial. The trial included 10 outpatient clinics with 64-detector CT units (Toshiba Aquilion 64 and Toshiba CLX). Special low-dose protocols have been developed for each unit with maximum effective dose of 1 mSv (in accordance with the requirements of paragraph 2.2.1, Sanitary Regulations 2.6.1.1192-03). The study involved 5,310 patients (53% men, 47% women) aged 18-92 years (mean age 62 years). Diagnosis verification was carried out in the specialized medical organizations via consultations, additional instrumental, laboratory as well as pathohistological studies. The results were then entered into the “National Cancer Registry”. Results. 5310 patients (53% men, 47% women) aged 18 to 92 years (an average of 62 years) participated in the LDCT-MLCS. The final cohort was comprised of 4762 (89.6%) patients. We have detected 291 (6.1%) Lung-RADS 3 lesions, 228 (4.8%) Lung- RADS 4A lesions and 196 (4.1%) Lung-RADS 4B/4X lesions. All 4B and 4X lesions were routed in accordance with the project's methodology and legislative documents. Malignant neoplasms were verified in 84 cases (1.76% of the cohort). Stage I-II lung cancer was actively detected in 40.3% of these individuals. For the first time in the Russian Federation we have calculated the number needed to screen (NNS) to identify one lung cancer (NNS=57) and to detect one Stage I lung cancer (NNS=207). Conclusions. Based on the global experience and our own practices, we argue that selective LDCT is the most systematic solution to the problem of early-stage lung cancer screening.

Download Full-text